Business Context and Reporting Period
This Form 8-K was filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) on February 10, 2011. The report discloses the receipt of the final tranche of federal grant funding under the Qualifying Therapeutic Discovery Project.
Key Financial Metrics
- Cash Position: Approximately $8.1 million following the grant receipt.
- Grant Funding Received: $234,000 (final tranche).
- Revenue, Profit, Margins, Debt: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change is the increase in liquidity resulting from the receipt of the $234,000 federal grant tranche, which raised the company's total cash position to approximately $8.1 million.
Outlook and Management Commentary
Management highlighted the successful conclusion of the federal grant funding cycle. The filing includes a news release (Exhibit 99.1) containing material non-public information regarding the funding and cash position. No specific forward-looking guidance, risk factors, or unusual items beyond the grant receipt were detailed in the text of this report.
Investor Verification Checklist
- Verify the total cash balance of $8.1 million in the company's most recent audited financial statements.
- Confirm the terms and conditions of the Qualifying Therapeutic Discovery Project grant.
- Review the attached news release (Exhibit 99.1) for additional operational details not summarized in the 8-K.